Skip to content

Released Mar 3, 2026, before the open

10-K filed Mar 3, 2026, 62 days after period end · 0001628280-26-013569

Q4 2025 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$838.00Kderived−61.6% vs Q4 2024−31.6% vs Q3 2025
Net Income-$46.08MderivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$48,608,000N/M
Operating Cash Flowderived-$37,256,000N/M
Free Cash Flowderived-$37,546,000N/M
Margins · derived
Operating margin-5800.5%−3774.7 pt vs Q4 2024
Net margin-5498.7%−3562.1 pt vs Q4 2024

What the release said

The release

Same quarter

MetricQ4 2025derived from reported figuresQ4 2024derived from reported figuresQ4 2023derived from reported figuresQ4 2022derived from reported figures
Revenue$838.00K$2.18M$0.00—
Net Income-$46.08M-$42.28M-$65.64M-$39.28M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Prime Medicine, Inc. · CIK 1894562 · Engraved from SEC EDGAR